Announces Spinal Muscular Atrophy Market to Witness Impressive CAGR 21.35% and surpass US$ 16.9 billion by 2030
Posted July 18, 2023 by nikita07072002
" Spinal Muscular Atrophy Market, By Disease Type (Type I, Type II, Type III, and Type IV), By Age (Infant and Adult), By Treatment (Drug Therapy and Gene Therapy)
Feature News
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/82
Key Highlights:
• In July 2021, Roche has launched a spinal muscular atrophy (SMA) treatment drug in India priced at around 6lakhper bottle. The drug Evrysdi is approved for the treatment of SMA in adults and children 2 months of age and older, Roche said it was approved by the Indian health authorities after reviewing its efficacy and safety data from 3 global clinical studies designed to represent a broad spectrum of people living with SMA.
• In July 2021, SadBaby has pledged to help SMA (Spinal Muscular Atrophy) patients in improving their life and ensuring that no child is left uncured. The project launched by SadBaby focuses on gathering funds through their supporters and investors and utilizes it for meeting the financial requirements of the SMA patients.
-- END ---
Share
| Contact Email | [email protected] |
| Issued By | nikita |
| Phone | 91 7775049802 |
| Business Address | BadilloStreet |
| Country | United States |
| Categories | Health |
| Tags | spinal muscular atrophy market trends |
| Last Updated | July 18, 2023 |